HOME
ABOUT IASO
Company Overview
Management Team
Scientific Advisory Board
Partnership
SCIENCE & PRODUCTS
Pipeline
Technology Platforms
Manufacturing
Publictaions
Expanded Access
NEWS
Press Release
Media Report
CAREERS
Working at IASO
Opportunities
CONTACT
中文简体
中文繁体
English
العربية
NEWS
Press Release
Media Report
Search
01
2023-07
IASO Bio and Innovent Updated Efficacy and Safety Clinical Data of Equecabtagene Autoleucel（BCMA CAR-T Cell Therapy）for Multiple Myeloma at the 2023 ASCO Annual Meeting
06
2023-04
IASO Bio’s partner Cabaletta Receives FDA Clearance of IND Application for CABA-201 for Treatment of SLE
13
2023-02
IASO Bio Announces CT103A Granted Regenerative Medicine Advanced Therapy (RMAT) and Fast Track (FT) Designations by the FDA
18
2023-01
IASO Bio Raises Nearly $75 Million in Series C1 Funding
22
2022-12
IASO Bio Announces U.S. FDA Approval of Clinical Trial Application for BCMA CAR-T CT103A for Relapsed/Refractory Multiple Myeloma
21
2022-11
Umoja Biopharma and IASO Biotherapeutics Announce Research Collaboration to Bring Off-the-Shelf Therapies to Patients with Hematological Malignancies
11
2022-10
Cabaletta Bio and IASO Biotherapeutics Announce Exclusive Worldwide License Agreement for Clinically Validated CD19 Binder
19
2022-08
World's First CAR-T for NMOSD Treatment, IASO Biotherapeutics' Equecabtagene Autoleucel, Receives IND Approval by NMPA
13
2022-06
IASO Bio and Innovent Present Updated Data of BCMA CAR-T Cell Therapy（Equecabtagene Autoleucel）at EHA 2022
02
2022-06
IASO Bio and Innovent Jointly Announce the NMPA Acceptance of the New Drug Application for Equecabtagene Autoleucel for the Treatment of Relapsed and/or Refractory Multiple Myeloma
<
4
5
6
7
8
>
